We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Gene Logic Completes Sale of Genomics Assets to Ocimum Biosolutions
News

Gene Logic Completes Sale of Genomics Assets to Ocimum Biosolutions

Gene Logic Completes Sale of Genomics Assets to Ocimum Biosolutions
News

Gene Logic Completes Sale of Genomics Assets to Ocimum Biosolutions

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Gene Logic Completes Sale of Genomics Assets to Ocimum Biosolutions"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Gene Logic Inc. has announced that it completed the sale of its Genomics assets to Ocimum Biosolutions Ltd., a global life sciences R&D enabling company. As a result of the sale, Gene Logic Inc. received $7 million in exchange for its genomics assets; an additional $3 million is payable pursuant to a promissory note due 18 months from the date of closing.

Ocimum has assumed certain liabilities associated with the Genomics assets and business. The sale was approved by Gene Logic Inc. shareholders earlier this week. The Gene Logic name transfers to Ocimum Biosolutions and the Company, formerly named Gene Logic Inc., now is renamed Ore Pharmaceuticals Inc. The company’s stock will trade under the ticker symbol GLGC for a few days and then will trade under its new ticker symbol ORXE.

In addition to the drug repositioning and development business, the Company retains specified assets and capabilities related to molecular diagnostics and will continue to explore strategic alternatives for these assets.

Advertisement